BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) issued the following statement regarding today's indictment of a former employee in connection with the promotional activities for Actimmune(R) (interferon gamma-1b) during a period that ended in June of 2003.
"Today's indictment concerns conduct by a former employee who left the company more than four years ago.
"In 2006, InterMune settled all government claims related to that conduct, without criminal sanctions against the company. At the time, the government acknowledged that InterMune fully cooperated with its investigation and had instituted numerous and comprehensive compliance changes before the investigation even began. Today's government action does not affect the Company's settlement in any way.
"In today's action, the government is bringing charges against a former employee, not against InterMune, its current employees or its Directors.
"Since 2004, InterMune has been a transformed company with a new management team, a rigorous compliance program and a promising pipeline focused on serious pulmonary and hepatic diseases.
"We have taken great strides to put this matter behind us and have focused our resources on what we believe is a promising future for our Company and our shareholders."
The individual charged today was Scott Harkonen, formerly President, Chief Executive Officer and a Director of InterMune.
InterMune is a biotechnology company focused on the research,
development and commercialization of innovative therapies in pulmonology
and hepatology. InterMune has a research and development portfolio
addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (H
|SOURCE InterMune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved